Investor Presentaiton

Top-tier talent Differentiated process Scalable platform Positive market backdrop supports strong pipeline trends Strong growth in initial reviews Initial reviews >200 +50% >300 >265 Opportunity set increasing Robust royalty acquisition activity 40 In-depth reviews +53% 50 61 Announced transaction value (+37% $3.0bn $2.4bn $2.2bn 2019 2020 2021 2019 2020 2021 2019 2020 2021 Pre-IPO Post-IPO ROYALTY PHARMA IPO: initial public offering 64 62

View entire presentation